Mounjaro Costs Across Federal Programs, Compared

Last updated 35 minutes ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

A government purchasing price for Mounjaro can be far removed from the bill at the pharmacy. In the VA system, the published brand-name medication copay starts at $11 for up to 30 days, while its purchasing catalog lists one four-pen Mounjaro package at $835.60.

Mounjaro has no single federal patient price: the bill depends on the program, coverage approval and where the prescription is filled.

Under Medicare Part D drug coverage, cash purchases through TrumpRx do not count toward the annual limit at which patients stop paying for covered prescriptions. Paying cash may lower a pharmacy bill without bringing the patient closer to that limit.

Compare patient costs before purchasing prices

Mounjaro is approved to improve blood-sugar control alongside diet and exercise in adults and children age 10 and older with type 2 diabetes, and to reduce major cardiovascular-event risk in adults with type 2 diabetes at high risk for those events. Its diabetes approval does not establish coverage for a prescription written for weight loss.

Mounjaro acts on the glucagon-like peptide-1 (GLP-1) receptor as well as the glucose-dependent insulinotropic polypeptide receptor. The single-dose Mounjaro pens come in six strengths, from 2.5 to 15 milligrams per 0.5 milliliter, and are administered once weekly. Keep the strength, package and supply period the same when asking for competing quotes.

The annual Medicare limit, a state Medicaid copay and a monthly cash offer measure different things. The TRICARE figures describe drug categories, so they cannot substitute for checking Mounjaro’s own coverage and category.

This comparison belongs to the GovFacts series on drugs and medications.

Medicare covers through the plan, not a national Mounjaro price

Medicare beneficiaries can add Part D prescription coverage to Original Medicare, while most Medicare Advantage plans include drug coverage. Part D plans have different lists of covered drugs and can use prior authorization, step therapy and quantity limits. Prior authorization requires the plan’s approval; step therapy can require trying another medicine first.

A price quote is useful only after the plan confirms that the prescription qualifies for its coverage. A covered-drug cap cannot turn a denied prescription into a covered one.

A copay is a fixed pharmacy charge; coinsurance is a percentage of the drug’s cost.

A Part D deductible can be no more than $615 in 2026 or $700 in 2027, and some plans have no deductible. The covered-drug out-of-pocket cap rises to $2,400 in 2027, and after reaching the cap beneficiaries pay nothing more out of pocket for covered Part D drugs. The deductible is the initial spending threshold; the annual cap is the point at which covered-drug patient charges stop.

After the deductible, Medicare describes the initial coverage stage as 25 percent coinsurance for generic and brand-name drugs; certain payments made on the patient’s behalf, including Extra Help, count toward the annual cap.

Medicare says cash purchases through TrumpRx or drug-discount programs do not count toward its deductible or out-of-pocket maximum. A cheaper cash transaction may therefore leave a patient farther from the covered-drug cap than an insurance claim would.

People with full Medicaid coverage, state help paying their Medicare Part B premium, or Supplemental Security Income receive Extra Help automatically; others can apply. Medicare states that Qualified Medicare Beneficiary program recipients with Extra Help pay no more than $12.65 in 2026 for each drug their Part D plan covers. That is a covered-drug ceiling for the specified group, rather than a universal Mounjaro price.

The Medicare Prescription Payment Plan spreads out-of-pocket prescription costs across monthly payments without lowering the total owed. It addresses the timing of a bill, not the coverage decision or the underlying charge.

Negotiation and new drug-access programs are separate questions

Mounjaro is absent from the complete selected-drug list for Medicare negotiated prices taking effect in 2026. It is also absent from the complete list for 2027, which includes Ozempic, Rybelsus and Wegovy. Mounjaro is not on the complete selected-drug list for 2028 either. Another diabetes drug’s selection does not establish a negotiated price for Mounjaro.

The Centers for Medicare & Medicaid Services says its BALANCE model will not launch in Medicare in 2027 and that the Medicare GLP-1 Bridge will extend through December 31, 2027. The Bridge’s eligible-product list includes Foundayo, Wegovy injections and tablets, and Zepbound KwikPen, but does not include Mounjaro. The Bridge’s advertised access should therefore not be treated as a Mounjaro benefit.

For eligible products and patients, the Bridge charges $50 outside the Part D benefit; that copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply.

Medicaid prices depend on the state and the member

Medicaid covers eligible low-income adults, children, pregnant women, older adults and people with disabilities, and states administer the program under federal requirements. All states provide outpatient prescription-drug coverage in Medicaid. Applications and questions about eligibility go to the state Medicaid agency.

California Medi-Cal Rx restricts Mounjaro coverage to type 2 diabetes and does not cover its use for weight loss. The state’s standard $0 pharmacy copay answers the price question only after the coverage conditions are met.

Some Medi-Cal members have a monthly share of cost, and a pharmacy claim is denied for an unmet share of cost until that amount has been satisfied. For those members, a zero copay does not mean the household faces no initial spending requirement.

Medicaid generally limits cost sharing to nominal amounts and exempts groups including children, terminally ill people and institutional residents. Emergency, family-planning and pregnancy-related services, and preventive services for children, cannot carry out-of-pocket charges. States can impose higher alternative charges on certain groups with income above 100 percent of the federal poverty level, subject to a cap of 5 percent of family income.

Federal law generally protects manufacturer drug-pricing information supplied for Medicaid rebate calculations from disclosure, with specified exceptions. A published patient copay cannot be used to reconstruct Medicaid’s net acquisition cost for Mounjaro.

CMS includes all formulations of Mounjaro in the BALANCE model for already-covered indications such as type 2 diabetes and for weight management. A model’s drug list does not establish that a particular state has joined or that an individual beneficiary has been approved.

Veterans and military families face different systems

VA patient copays and Federal Supply Schedule purchases

VA health-care eligibility generally requires qualifying active military service and a discharge that is not dishonorable; minimum-service rules and exceptions can also apply. The VA’s April 2026 national formulary decision added Mounjaro with prior authorization. Eligibility for VA care and approval of the prescription are separate hurdles.

For people who enlisted after September 7, 1980, or entered active duty after October 16, 1981, VA generally requires 24 continuous months of service or the full called-up period; exceptions include service-related disability, hardship and early-out discharges.

Veterans in priority group 1 pay no medication copay, while some veterans in groups 2 through 8 owe copays for non-service-connected conditions, subject to a $700 annual medication-copay cap. The cap concerns VA medication copays, rather than every health expense a veteran might have.

The VA’s public pharmaceutical catalog lists a four-pen package of Mounjaro 2.5 milligrams per 0.5 milliliter, NDC 00002-1506-80, at a Federal Supply Schedule price of $835.60 under contract 36F79725D0226. Federal Supply Schedule contracts make products available to eligible government purchasers under contract terms. The $835.60 buys a specified package for an eligible purchaser; it is not the veteran’s pharmacy copay.

Nor does a listed contract price disclose every government purchaser’s eventual net cost. Keep that purchasing column separate from patient charges when comparing federal programs.

TRICARE costs change with the pharmacy channel

TRICARE serves eligible uniformed-service members, retirees and family members, with eligibility determined by the uniformed services and recorded in the Defense Enrollment Eligibility Reporting System. TRICARE covers Mounjaro for type 2 diabetes subject to clinical criteria and medical-necessity paperwork; the provider’s prior-authorization form is waived if another diabetes drug is documented in the member’s TRICARE pharmacy record within the previous 720 days. The pharmacy’s covered-drug quote must reflect both the approved prescription and its actual formulary category.

For most beneficiaries, a military pharmacy charges $0 for formulary drugs for up to 90 days, while non-formulary drugs generally require medical necessity to be available there. A non-formulary drug costs $85 through home delivery for up to 90 days or at network retail for up to 30 days; TRICARE Prime Remote has $0 rates, and medically retired sponsors and certain survivors follow different rates. A 90-day home-delivery charge and a 30-day retail charge are not directly comparable monthly prices.

TRICARE’s catastrophic cap counts covered prescription copays along with eligible deductibles, enrollment fees and other covered-care cost shares. Noncovered services, point-of-service charges, specified program premiums and charges above the allowable amount are among the costs excluded from that cap. A pharmacy payment can advance the cap without every payment connected to health coverage doing so.

Federal employee and Marketplace plans require a plan-level quote

FEHB: the program is not the drug-price schedule

Most federal employees can elect FEHB coverage unless their position is excluded; enrollment can occur within 60 days after the employee’s start date, during Open Season or after a qualifying life event. The 2026 Blue Cross and Blue Shield Federal Employee Program (FEP) formulary lists Mounjaro in Tier 2 under Standard, Basic and Focus. A formulary tier identifies a benefit category, not one price shared by every FEHB plan or option.

OPM’s 2026 Blue Cross and Blue Shield Service Benefit Plan brochure describes Standard and Basic options.

In that brochure’s preferred-retail Tier 2 diabetic-medication category, Standard members pay 20 percent of the plan allowance for up to a 90-day supply, with no deductible; Basic members pay $35 for up to 30 days or $65 for 31 to 90 days. When Medicare Part B is primary, the Basic preferred-retail rate shown for that category is $30 for up to 30 days or $60 for 31 to 90 days. These are named-option benefit rates, subject to the prescription’s approval and applicable pharmacy rules.

FEP requires advance approval for certain drugs and can require periodic renewal; a retail prescription filled before necessary approval can initially cost the full price. Ask the plan to quote the exact option, approved prescription, pharmacy and supply period together.

For 2026, FEP Basic’s preferred-provider out-of-pocket limit is $7,500 for Self Only or $15,000 for Self Plus One or Self and Family, counting eligible coinsurance and copayments. The brochure excludes charges above the plan allowance and expenses beyond benefit limits, among other exclusions, from catastrophic protection.

Marketplace: coverage and deductibles vary

Marketplace enrollment generally requires living in the United States, U.S. citizenship or nationality or lawful presence, and not being incarcerated; people with Medicare cannot enroll in Marketplace coverage. Some Marketplace plans have a separate deductible for prescription drugs. That makes the remaining drug deductible part of the price question, even when the medicine is covered.

For 2026, a Marketplace plan’s out-of-pocket limit can be no more than $10,600 for an individual or $21,200 for a family for covered in-network care. Noncovered services, out-of-network care and charges above the allowed amount do not count toward that limit. A prescription handled as a covered plan benefit is therefore different from purchasing a noncovered drug independently.

TrumpRx leads to a cash purchase outside coverage

TrumpRx’s Mounjaro product page directs buyers to LillyDirect. The manufacturer’s offer, not the government catalog’s display alone, supplies the product and purchase terms.

Lilly’s self-pay terms require an approved-label prescription for personal use by an adult age 18 or older living in the United States or Puerto Rico, and define a month as four pens. Drug approval for some children does not extend this adult-only cash offer to them.

The self-pay purchase cannot be submitted for reimbursement to commercial insurance or a government program, and it cannot count toward an insurance deductible, out-of-pocket limit or Medicare’s true out-of-pocket spending. Compare the cash bill with the covered claim and its effect on the annual limit, rather than choosing from the sticker amounts alone.

Mounjaro’s separate savings-card program requires commercial insurance and excludes people enrolled in Medicare, Medicaid, TRICARE and other listed government-funded programs. Those savings-card restrictions should not be mistaken for the different self-pay purchase terms.

Get the coverage decision and the price together

Ask the pharmacy or benefit administrator for a quote that specifies the drug strength, number of pens, supply period, approval status and whether the transaction is a covered claim or cash purchase. Then ask which part of the payment counts toward the plan’s deductible and annual limit.

A Part D exception requires a prescriber’s statement explaining the medical reason for approval; a denied coverage decision can be appealed through the plan. Marketplace drug exceptions can also rely on a prescriber’s explanation that covered alternatives would not work or could be harmful.

The patient or prescriber can request a Part D coverage determination or exception by model form, letter or phone, and can request an expedited decision if waiting could seriously jeopardize life, health or the ability to regain maximum function.

If a Marketplace exception is approved, the plan generally treats the drug as covered, charges its highest covered-drug copayment and counts the payment toward the deductible or out-of-pocket limit; a denied exception can receive independent review. An approved exception can change both the immediate charge and how that spending is credited.

For a state Medicaid-agency denial of benefits or services, the written notice must explain how to request a fair hearing and the request deadline. Hearing procedures differ by state, and another state agency may handle them; contact the state Medicaid agency for the applicable steps.

For a denied TRICARE prescription or prior authorization, the program directs members to its pharmacy contractor, Express Scripts. For an FEHB claim dispute, follow the brochure’s disputed-claims section and ask the plan in writing to reconsider; OPM review follows only after the plan has reconsidered or had an opportunity to do so.

For a VA decision about whether to prescribe a particular medicine, the Clinical Appeals route starts with the facility’s patient advocate. Use the denial notice to identify the applicable review process rather than assuming every federal program has the same appeal rules.

The useful comparison ends with an approved prescription and a transaction-specific quote. That is the price the patient can act on, with the annual-limit consequences understood before the purchase.